Medigene (ETR:MDG1) Shares Down 2.7%


Share on StockTwits

Medigene AG (ETR:MDG1) dropped 2.7% during mid-day trading on Tuesday . The stock traded as low as €3.75 ($4.41) and last traded at €3.75 ($4.41). Approximately 7,500 shares traded hands during trading, a decline of 98% from the average daily volume of 306,207 shares. The stock had previously closed at €3.86 ($4.54).

The company has a market capitalization of $96.41 million and a PE ratio of -3.19. The company’s 50 day moving average price is €3.90 and its 200-day moving average price is €3.91. The company has a current ratio of 3.23, a quick ratio of 3.16 and a debt-to-equity ratio of 9.70.

Medigene Company Profile (ETR:MDG1)

Medigene AG, a clinical stage immuno-oncology company, focuses on the development of T cell immunotherapies for the treatment of cancer. The company operates in two segments, Immunotherapies and Other products. It is developing personalized T cell-based therapies, with a focus on T cell receptor-modified T cells and associated projects, which are in pre-clinical and clinical development.

Featured Story: What strategies should day traders use to execute a trade?

Receive News & Ratings for Medigene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medigene and related companies with MarketBeat.com's FREE daily email newsletter.